Always taking RISK - do your own DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thought about picking up either GORAF or NMUS and went with the other since i already have a larger position here, but both looking great.
Congrats guys, best is yet to come. GO LIB
Exactly, why all the restricting and management changes and talk of up list if nothing big is going on behind closed doors. I believe the data that was presented back in November got a great results and will be taking it to Trials, and per ceo interview I watched looks like they can take much faster timeline than usual
Added little more to my position, I have a feeling we’re going to be getting a ton of news and updates on pipeline and company overall. Feet up.
GO Nemus
Looking forward to any type of update to bring little more awareness to the cannabis investors community. 2018 going to be a great year.
Impressive pipeline for sure. Nemus is the sole developmental and commercialization partner with the University and has exclusive, global licenses to intellectual property related to these molecules. Those licenses include access to intellectual property for both a prodrug of tetrahydrocannabinol (THC) and an analogue of cannabidiol (CBD). The THC-prodrug is being developed as a therapeutic agent for glaucoma and chemotherapy-induced nausea and vomiting (CINV). The analogue of CBD is being explored as a possible therapeutic for chemotherapy-induced peripheral neuropathy (CIPN) and other pain syndromes. Lastly, Nemus is developing cannabinoid-based platforms for use as anti-infectives, especially for use against bacteria and viruses that have developed resistance to established therapies.
Liberty Leaf is ready to RockNRoll, let’s Rock!
GO LIB
Should be moving north moving forward. Going to be a great month. Could easily see 0.50 before closing of acquisition by end of the month.
Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017
Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017
Summary
This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.
Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. There are a total of 28 products in development for this indication, by 20 companies. Key companies operating in this pipeline space include Helsinn, Luxena Pharmaceuticals, Aphios, Nemus Bioscience and Tesaro.
Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. There are a total of 41 products in development for this indication, by 31 companies and one academic institution. Key companies operating in this pipeline space include Bolder Biotechnology, USV, Apotex, Biocon, Biogenomics, Generon and Pfizer.
Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. There are a total of 16 products in development for this indication, by 14 companies. Key companies operating in this pipeline space include Chong Kun Dang and Tolero Pharmaceuticals.
Finally, chemotherapy-induced peripheral neuropathy (CIPN) is a further potential side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. There are a total of 41 products in development for this indication, by 34 companies and four academic institutions. Key companies operating in this pipeline space include Apexian Pharmaceuticals, Celgene and Metys Pharmaceuticals.
The dominant molecular targets vary across each of the four pipelines. In CINV and CIPN, there is a relatively diverse range of targets which are being studied. The 5-hydroxytryptamine receptor 3 and substance P receptors are most commonly being studied in CINV, as are the cannabinoid receptors 1 and 2. There is some overlap between this and the CIPN pipeline, with cannabinoid receptors being present amongst the relatively diverse range of targets in development, although with the glutamate ionotropic receptor NMDA-type being the most-frequently selected target.
In chemotherapy-induced neutropenia, on the other hand, the granulocyte colony stimulating factor receptor is overwhelmingly the target of choice, accounting for virtually the entire pipeline. Similarly, the erythropoietin receptor makes up the majority of the chemotherapy-induced anemia pipeline. This reflects the relatively focused nature of R&D within these two indications.
Scope
Which companies are the most active within the pipeline for toxicology therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in the field of toxicology therapeutics?
Reasons to buy
Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
http://www.military-technologies.net/2018/01/05/toxicology-cluster-chemotherapy-related-toxicity-drug-development-pipeline-review-2017/
I wonder if all of the Emerald shareholders have realized that their company is in majority control of Nemus Bioscience $NMUS and bought shares of them as well. Investors should ask why $EMHTF "Emerald" is infusing cash and essentially taking over $NMUS - the glaucoma drug is amazing.
https://ih.advfn.com/p.php?pid=nmona&article=76397369
Good to see private placement finalized. Now company can move forward with business as usual and start making deals. Just the beginning here with them. Great time to be here.
Just the beginning to greatness IMO. So glad i jumped in to this. One of the drugs goes into trial then were talking big bucks $$$
I highly doubt they will do any of that. The current SS is already tiny enough to get them over the hump.
NMUS Security Details
Share Structure
Market Value1 $6,052,109 a/o Jan 05, 2018
Authorized Shares 236,000,000 a/o Dec 29, 2017
Outstanding Shares 33,622,829 a/o Dec 29, 2017
-Restricted 12,573,192 a/o Dec 29, 2017
-Unrestricted 21,049,637 a/o Dec 29, 2017
Held at DTC 18,874,535 a/o Dec 29, 2017
Float 14,218,313 a/o Mar 07, 2017
Par Value 0.001
Missed the date when reading the PR originally, thanks :)
What makes you think January 28 is the date, thanks.
The more I read about their pipeline is more I believe there is something special brewing here. Highly suggest reading all of their past Press Releases and pipeline. No wonder Emerald wants to take control over them.
http://www.nemusbioscience.com/investor-relations/investor-news/default.aspx
Got mine to :)
Canadian side looks like it wants $1, we should technically follow as they go.
They did say it would be on the 10th, so who knows, but we do have the management in place that definitely know what they are doing. Going to be a great year.
Nice action here, people must’ve re read the last PR carefully and noticed how it stated how they want to up list ;)
Looking great here as always, license news soon maybe?
Old but great article. $NMUS Bioscience highlighted in BioWorld: "Can cannabinoids earn respect? New candidates not just blowing smoke"
http://www.bioworld.com/content/can-cannabinoids-earn-respect-new-candidates-not-just-blowing-smoke
NMUS is one of the biggest sleepers in OTC that’s ready to make some serious noise. Happy to be here with as the company is now looking to restructuring everything with Emerald taking control over the company.
Very good sign, rumors have it that license will be granted soon.
GO Liberty Leaf
Due Diligence Report By Equity Insights on Liberty Leaf Holdings.
http://www.equityinsight.ca/reports
Veterinarians seek permission to research marijuana for pets.
http://www.sltrib.com/news/health/2017/12/08/veterinarians-seek-permission-to-research-marijuana-for-pets/
These guys have a class management and 2018 is going to be a banner year for them.
GO LIBFF
This flies to multi dollars with news, patience will be rewarded big time here.
Tweet from company Twitter
Nutritional High is featured in this @insidrfinancial article regarding the stock and cannabis industry investment.
https://insiderfinancial.com/nutritional-high-i-otcmktssplif-is-an-emerging-cannabis-play/174624/
Nutritional High is featured in this @insidrfinancial article regarding the stock and cannabis industry investment. More: https://t.co/x9y3RWpgkd pic.twitter.com/Ub3Hw04e6g
— Nutritional High (@NutritionalHigh) January 4, 2018
Should be epic as a good buddy of mine said once ;)
Haha, yes it has been a crazy day so far, but gotta love the red days, awesome if you’re a long and only just adding for the long run. Added at .14, not much but just a little more to my pile ;)
Would love to add some at .1409 if anyone wants to sell me some ;)
$BLGVF BELGRAVIA CAPITAL INTERNATIONAL announces LOI with R&D Pharma Corp.
https://www.otcdynamics.com/blgvf-belgravia-capital-international-announces-loi-with-rd-pharma-corp/
Nice news:
Liberty Leaf's Upgrades to the Just Kush Facility Nearly Complete
http://www.newswire.ca/news-releases/liberty-leafs-upgrades-to-the-just-kush-facility-nearly-complete-668016093.html
Another great day here. I stopped looking on this board, this will be a big winner. $3-5 by end of January imo.
GO CBW
Perfect..Thanks bud.
Thanks bud, can’t wait for this to be finalized, definitely going higher. We may have hit the jock pot :)
This is gonna be a multi dollars once this deal is finalized. I’m keeping this one for a while.
SPLIFFIN has become an icon in Los Angeles. With sales increasing to well over $20,000,000 USD last year, the company has agreed to enter into an agreement with Tabu to launch SPLIFFIN CANADA. All of the branded products developed in California will be manufactured in Canada. SPLIFFIN is known as the APPLE of cannabis, with its keen eye for design and aesthetics, along with a high level of quality. All SPLIFFIN products should be considered premium just as the branding represents. No expense was spared, art meets science when it comes to the SPLIFFIN line. The company has developed a full compliment of oils and pens, specifically designed for the needs of patients. SPLIFFIN CANADA will launch with its own state of the art lab and grow facility in order to offer its full product line for this market and for export world wide. SPLIFFIN USA will also provide 75% of all financing required, for the construction of a grow facility in Canada, including financing for subsequent expansion over several years. This will be Tabu’s core project, adding tremendous value to Tabu as well as a quality supply of products to the company’s lab and partners.
http://tabu.co/projects/
This thing is going to fly once news hits.
#GOGOR #GOGORAF ??